Cubist Systematic Strategies, LLC Uro Gen Pharma Ltd. Transaction History

Cubist Systematic Strategies, LLC

$17.3 Billion
Q1 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 6,150 shares of URGN stock, worth $97,662. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,150

Previous 142 4230.99%

Holding current value

$97,662

Previous $2,000 4500.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$13.81 - $19.33 $82,970 - $116,134	6,008 Added 4230.99%	6,150 $92,000
Q4 2023 Feb 14, 2024	SELL	$10.87 - $15.93 $1.41 Million - $2.07 Million	-129,930 Reduced 99.89%	142 $2,000
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $1.04 Million - $2.67 Million	117,718 Added 952.87%	130,072 $1.82 Million
Q2 2023 Aug 14, 2023	BUY	$8.75 - $14.29 $108,097 - $176,538	12,354 New	12,354 $127,000
Q1 2020 May 15, 2020	SELL	$13.68 - $34.6 $20,219 - $51,138	-1,478 Closed	0 $0

Q4 2019 Feb 14, 2020	BUY	$21.11 - $34.86 $22,777 - $37,613	1,079 Added 270.43%	1,478 $49,000
Q3 2019 Nov 14, 2019	SELL	$23.83 - $36.44 $23 - $36	-1 Reduced 0.25%	399 $10,000
Q2 2019 Aug 14, 2019	SELL	$32.75 - $40.35 $354,944 - $437,313	-10,838 Reduced 96.44%	400 $14,000
Q1 2019 May 15, 2019	BUY	$35.47 - $54.55 $370,235 - $569,392	10,438 Added 1304.75%	11,238 $415,000
Q4 2018 Feb 14, 2019	BUY	$38.35 - $50.39 $26,960 - $35,424	703 Added 724.74%	800 $34,000
Q3 2018 Nov 14, 2018	SELL	$41.65 - $51.7 $274,765 - $341,064	-6,597 Reduced 98.55%	97 $5,000
Q2 2018 Aug 14, 2018	BUY	$48.35 - $65.33 $323,654 - $437,319	6,694 New	6,694 $333,000

Others Institutions Holding URGN

# of Institutions

113

Shares Held

24M

Call Options Held

46.9K

Put Options Held

44.3K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $361M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Uro Gen Pharma Ltd. Transaction History